The FDA has issued warning letters to five online peptide vendors, citing violations of the Federal Food, Drug, and Cosmetic Act for selling unapproved new drugs. The letters, reported by Pharmaphorum and dated August 24, 2026, name Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC (doing business as Tex Peptides).
The warning letters cite the sale of unapproved peptide products including semaglutide, tirzepatide, retatrutide, and other compounds. Pharmaphorum reports that the FDA gave the companies 15 days to respond, creating a potential enforcement window around September 8, 2026. However, standard FDA warning letter language typically requests a response within 15 working days of receipt, meaning the actual deadline may differ from that date.
What happened
According to Pharmaphorum, the FDA issued warning letters to the five vendors on August 24, 2026. The letters allege that the companies violated the FD&C Act by marketing unapproved new drugs through online platforms. The cited products include semaglutide, tirzepatide, retatrutide, and other peptides.
The named vendors are:
- Peak Performance Peptides
- Royal Peptides LLC
- NuScience Peptides LLC
- Peptide Partners LLC
- TXP Innovations LLC (doing business as Tex Peptides)
Pharmaphorum reports that the FDA set a 15-day response deadline from the August 24 issuance date, which would fall on or around September 8, 2026. However, FDA warning letters customarily request a written response within 15 working days of receipt. Because working days exclude weekends and holidays, the actual response deadline may fall later than September 8 depending on when each vendor received its letter. The exact September 8 date has not been independently verified beyond the Pharmaphorum report.
Why it matters
The warning letters represent a continued enforcement push by the FDA against online sellers of unapproved peptide products, particularly GLP-1 receptor agonists and related compounds that have proliferated through direct-to-consumer websites.
The response deadline marks the next concrete milestone in this enforcement cycle. If vendors fail to respond adequately, the FDA may pursue further regulatory or legal action against non-responsive vendors, consistent with standard warning letter procedures, though the specific form any such action might take has not been detailed in current reporting.
The action also has implications for telehealth platforms that source peptide products from these or similar vendors. Companies in the peptide supply chain may face increased scrutiny as the FDA continues to target unapproved drug sales.
What to watch next
- Whether the five named vendors submit responses within the FDA’s requested timeframe
- Whether the FDA publishes enforcement updates, injunctions, or additional actions following the response deadline
- Whether further warning letters or enforcement actions target additional online peptide sellers
- How telehealth platforms and compounding operations adjust sourcing or marketing practices in response
Sources
- Pharmaphorum: FDA issues warning letters to five unapproved GLP-1 websites
- FDA.gov: Royal Peptides LLC warning letter
Industry information only. Not medical or legal advice.
